Anebulo Pharmaceuticals Inc (ANEB) USD0.001

- Add to watchlist
- This stock can be held in a




Business summary
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing solutions for people suffering from cannabinoid overdose and substance addiction. The Company's lead product candidate, ANEB-001, is a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations. ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. CB1 antagonists bind to the CB-1 receptor and thereby reverse the action of cannabinoids such as tetrahydrocannabinol (THC). It has completed Phase I trials.
Contact details
Important dates
General stock information
- Short code:
- ANEB
- ISIN:
- US0345691036
- Market cap:
- $79.11 million
- Shares in issue:
- 23.34 million
- Sector:
- Pharmaceuticals
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.